{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:23:01Z","timestamp":1761016981172,"version":"3.40.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.juro.2012.11.020","type":"journal-article","created":{"date-parts":[[2012,12,9]],"date-time":"2012-12-09T05:16:32Z","timestamp":1355030192000},"source":"Crossref","is-referenced-by-count":18,"title":["Rapid Efficacy of the Highly Selective \u03b1<sub>1A<\/sub>-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies"],"prefix":"10.1097","volume":"189","author":[{"given":"Leonard S.","family":"Marks","sequence":"first","affiliation":[{"name":"University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc C.","family":"Gittelman","sequence":"additional","affiliation":[{"name":"South Florida Medical Research, Aventura, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Hill","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Volinn","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Hoel","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2012.11.020_bib1","series-title":"Urologic Diseases in America","first-page":"43","article-title":"Benign prostatic hyperplasia","author":"Wei","year":"2007"},{"key":"10.1016\/j.juro.2012.11.020_bib2","first-page":"S3","article-title":"Pathophysiology of lower urinary tract symptoms in the aging male population","volume":"7","author":"Lepor","year":"2005","journal-title":"Rev Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ncpuro0836","article-title":"Pharmacology of \u03b11-adrenoceptor antagonists in the lower urinary tract and central nervous system","volume":"4","author":"Andersson","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"\u03b11-Adrenoceptor subtypes and lower urinary tract symptoms","volume":"15","author":"Schwinn","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1476-5381.1995.tb15001.x","article-title":"Noradrenaline contractions of human prostate mediated by \u03b11A-(\u03b11c-)adrenoceptor subtype","volume":"115","author":"Marshall","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2012.11.020_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1994.tb17053.x","article-title":"Pharmacological evidence of distinct \u03b11-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery","volume":"113","author":"Hatano","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2012.11.020_bib7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0022-5347(05)67426-5","article-title":"Tissue selectivity of KMD-3213, an \u03b11-adrenoreceptor antagonist, in human prostate and vasculature","volume":"164","author":"Murata","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-002-0246-7","article-title":"Tamsulosin: an overview","volume":"19","author":"Chapple","year":"2002","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000019639","article-title":"A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing","volume":"33","author":"de Mey","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0026-895X(25)10243-5","article-title":"KMD-3213, a novel, potent, \u03b11a-adrenoceptor-selective antagonist: characterization using recombinant human \u03b11-adrenoceptors and native tissues","volume":"48","author":"Shibata","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.juro.2012.11.020_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-3565(24)29676-2","article-title":"In vivo demonstration of \u03b11A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues","volume":"296","author":"Yamada","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2012.11.020_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(96)00589-4","article-title":"Effect of KMD-3213, an \u03b11a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta","volume":"315","author":"Yamagishi","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.juro.2012.11.020_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(24)35074-8","article-title":"KMD-3213, a uroselective and long-acting \u03b11a-adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2012.11.020_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","article-title":"Silodosin, a new \u03b11A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men","volume":"98","author":"Kawabe","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2012.11.020_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000019996","article-title":"Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"H\u00f6fner","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2012.11.020_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003495-200666030-00002","article-title":"Effects of \u03b11-adrenoceptor antagonists on male sexual function","volume":"66","author":"van Dijk","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.juro.2012.11.020_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrborn","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2012.11.020_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia","volume":"51","author":"Lepor","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2012.11.020_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.eururo.2007.03.034","article-title":"The long-term outcome of medical therapy for BPH","volume":"51","author":"Madersbacher","year":"2007","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712054857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534712054857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2012.11.020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:45:46Z","timestamp":1745412346000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2012.11.020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":19,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1016\/j.juro.2012.11.020"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2012.11.020","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"type":"print","value":"0022-5347"},{"type":"electronic","value":"1527-3792"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}